KAINOS Laboratories (TSE:4556) LT-Debt-to-Total-Asset: 0.03 (As of Mar. 2026)

What is KAINOS Laboratories LT-Debt-to-Total-Asset?

KAINOS Laboratories TSE:4556 39 LT-Debt-to-Total-Asset is 0.03 as of Mar. 2026. GuruFocus rates TSE:4556 with a GF Score™ of 39/100 and a GF Value™ of 円1,282.10 (Significantly Overvalued). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. KAINOS Laboratories's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.03.

KAINOS Laboratories's long-term debt to total assets ratio declined from Mar. 2025 (0.06) to Mar. 2026 (0.03). It may suggest that KAINOS Laboratories is progressively becoming less dependent on debt to grow their business.

KAINOS Laboratories (TSE:4556) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

KAINOS Laboratories LT-Debt-to-Total-Asset Related Terms

KAINOS Laboratories LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for KAINOS Laboratories's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KAINOS Laboratories LT-Debt-to-Total-Asset Chart

KAINOS Laboratories Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.07

0.06

0.04

0.06

0.03

KAINOS Laboratories Semi-Annual Data
	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25	Sep25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.04	0.04	0.06	0.03	0.03

39GF Score

KAINOS Laboratories Inc TSE:4556

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

KAINOS Laboratories LT-Debt-to-Total-Asset Calculation

KAINOS Laboratories's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )	/	Total Assets (A: Mar. 2026 )
	=	329.432	/	9566.85
	=	0.03

KAINOS Laboratories's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	329.432	/	9566.85
	=	0.03

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.03 mean?

KAINOS Laboratories (TSE:4556) has a LT-Debt-to-Total-Asset of 0.03 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on KAINOS Laboratories and its competitors.

Is KAINOS Laboratories' LT-Debt-to-Total-Asset too high?

KAINOS Laboratories' current LT-Debt-to-Total-Asset is 0.03. Overall, KAINOS Laboratories has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does KAINOS Laboratories' LT-Debt-to-Total-Asset compare to ISRG and BDX?

KAINOS Laboratories' LT-Debt-to-Total-Asset of 0.03 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on KAINOS Laboratories and its competitors. KAINOS Laboratories's current LT-Debt-to-Total-Asset is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is KAINOS Laboratories stock overvalued right now?

Based on GuruFocus' analysis, KAINOS Laboratories (TSE:4556) is currently considered Significantly Overvalued. The stock's GF Value™ is 円1,282.10, compared to a current price of 円2,268.00 — trading 76.9% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.03. KAINOS Laboratories' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For KAINOS Laboratories (TSE:4556), the current LT-Debt-to-Total-Asset is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is KAINOS Laboratories (TSE:4556) Overvalued in 2026?

Based on GuruFocus' analysis, KAINOS Laboratories stock appears to be overvalued. The current stock price of 円2,268.00 is trading 76.9% above its estimated GF Value™ of 円1,282.10. GuruFocus considers KAINOS Laboratories to be Significantly Overvalued.

Key valuation signals for TSE:4556:

LT-Debt-to-Total-Asset: 0.03
GF Value™: 円1,282.10 vs. price of 円2,268.00 (76.9% above fair value)
GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the TSE:4556 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

KAINOS Laboratories Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies TSE:7702 TSE:3446 TSE:7775 TSE:9340 TSE:7980 TSE:7743 TSE:7813 TSE:7782 TSE:3154 TSE:7749 ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM

Address 38-18, Hongo 2-chome, Bunkyo-ku, Tokyo, JPN

Website http://www.kainos.co.jp

KAINOS Laboratories Inc is focused on the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products. It also manufactures, sells, and exports/imports physicochemical measuring equipment for medical use.

39GF Score

Get the complete analysis for TSE:4556

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,268.00

Price

円1,282.10

GF Value

View TSE:4556 Analysis

See LT-Debt-to-Total-Asset data for all stocks →